Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sarcoma, Alveolar Soft Part 1Recurrence 1Rectal Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hodgkin Disease 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 115fludarabine phosphate 67Mycophenolic Acid 62Etoposide 61Peripheral Blood Stem Cell Transplantation 58Tacrolimus 55Melphalan 48Filgrastim 48Busulfan 48Whole-Body Irradiation 47Doxorubicin 46Radiotherapy 42fludarabine 38Cyclosporine 38Brentuximab Vedotin 38Vinblastine 35Granulocyte Colony-Stimulating Factor 35Antilymphocyte Serum 30Methotrexate 29Dacarbazine 29Gemcitabine 28Rituximab 26Nivolumab 25Prednisone 24Bleomycin 24Vincristine 22pembrolizumab 21Carmustine 21Cytarabine 20thymoglobulin 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hodgkin Disease × Pyridoxine × Clear all
NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡